MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/meg.0000000000003169

Медицинская библиотека · European journal of gastroenterology & hepatology · 2026

Tissue penetration of anti-tumour necrosis factor therapy in perianal fistulising Crohn's disease: a proof-of-concept study.

Anandabaskaran Sulak, Liu Zhigang, Hanna Luke, Lung Phillip, Alexander James L, Powell Nick, Connor Susan J, Tozer Phil, Hart Ailsa

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Perianal fistulising Crohn's disease (pfCD) remains a therapeutic challenge, with a limited sustained response to biological therapy. Although higher serum anti-tumour necrosis factor (TNF) levels are associated with improved fistula healing, tissue pharmacokinetics in pfCD are poorly understood. This proof-of-concept study aimed to establish the feasibility of quantifying anti-TNF concentrations within fistula tissue and evaluate their relationship with serum levels and treatment outcomes.

METHODS

Paired blood and fistula tract biopsies were obtained from 14 patients (infliximab, seven; adalimumab, seven) with active pfCD on established anti-TNF therapy (>14 weeks post-induction). The serum was processed by centrifugation within 8 h and stored at -80°C. Fistula tract biopsies were snap-frozen, homogenised, and extracted using an ELISA buffer proportional to tissue weight. Anti-TNF levels in the serum and tissue supernatants were quantified using standard and high-sensitivity ELISA assays, respectively.

RESULTS

All patients had detectable anti-TNF concentrations in both serum and fistula tissues. Tissue and serum levels showed a moderate positive correlation ( r  = 0.45, P  = 0.09), with a stronger and statistically significant association in the infliximab subgroup ( r  = 0.81, P  = 0.01). Higher fistula-to-serum ratios, reflecting enhanced tissue penetration, tended towards improved clinical and radiological outcomes and lower perianal disease activity index scores, although the difference was not statistically significant.

CONCLUSION

Anti-TNF levels in perianal fistula tissue are measurable and correlated with serum concentrations, supporting a mechanistic link between systemic exposure and local drug penetration. These findings highlight the feasibility of tissue-level pharmacokinetic assessments and warrant validation in larger prospective cohorts.

Для цитирования: Anandabaskaran Sulak, Liu Zhigang, Hanna Luke, Lung Phillip, Alexander James L, Powell Nick, Connor Susan J, Tozer Phil, Hart Ailsa. Tissue penetration of anti-tumour necrosis factor therapy in perianal fistulising Crohn's disease: a proof-of-concept study.. European journal of gastroenterology & hepatology. 2026. DOI: 10.1097/meg.0000000000003169.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.